Stay updated on Clinical Trial of KB103 for DEB Patients
Sign up to get notified when there's something new on the Clinical Trial of KB103 for DEB Patients page.

Latest updates to the Clinical Trial of KB103 for DEB Patients page
- CheckyesterdayChange DetectedThe page shows a minor revision update from v3.3.3 to v3.3.4, likely a metadata or formatting change that does not affect study details. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check8 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedIntroduces a Locations section with California as a study site and updates the revision to v3.3.3. The previous California Locations entry and the HHS Vulnerability Disclosure link were removed.SummaryDifference0.2%

- Check51 days agoChange DetectedPublication section includes a minor wording update clarifying that publications are provided voluntarily and relate to the study results. A revision tag was added (Revision: v3.3.2) and the previous tag (Revision: v3.2.0) was removed.SummaryDifference0.1%

- Check58 days agoChange DetectedThe deletion removes a site-wide notice about government funding status and NIH Clinical Center operations. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check72 days agoChange DetectedThe new screenshot shows only minor UI changes with no changes to core study details, objectives, inclusion criteria, or reported outcomes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check101 days agoChange DetectedAdd: new government operating-status notice, a new resource entry for Epidermolysis bullosa dystrophica, and version to v3.2.0. Delete: version v3.1.0.SummaryDifference5%

Stay in the know with updates to Clinical Trial of KB103 for DEB Patients
Enter your email address, and we'll notify you when there's something new on the Clinical Trial of KB103 for DEB Patients page.